Last reviewed · How we verify
Aspirin combined with clopidogrel
Aspirin combined with clopidogrel is a Dual antiplatelet agent Small molecule drug developed by The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School. It is currently FDA-approved for Acute coronary syndrome, Secondary prevention after myocardial infarction, Prevention of stent thrombosis after percutaneous coronary intervention.
Aspirin and clopidogrel together inhibit platelet aggregation through different pathways to prevent blood clots.
Aspirin and clopidogrel together inhibit platelet aggregation through different pathways to prevent blood clots. Used for Acute coronary syndrome, Secondary prevention after myocardial infarction, Prevention of stent thrombosis after percutaneous coronary intervention.
At a glance
| Generic name | Aspirin combined with clopidogrel |
|---|---|
| Sponsor | The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School |
| Drug class | Dual antiplatelet agent |
| Target | Cyclooxygenase (COX) and P2Y12 receptor |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | FDA-approved |
Mechanism of action
Aspirin irreversibly inhibits cyclooxygenase (COX), reducing thromboxane A2 production and platelet activation. Clopidogrel is a P2Y12 receptor antagonist that blocks ADP-mediated platelet aggregation. Combined, they provide dual antiplatelet therapy with complementary mechanisms to reduce thrombotic events.
Approved indications
- Acute coronary syndrome
- Secondary prevention after myocardial infarction
- Prevention of stent thrombosis after percutaneous coronary intervention
- Stroke prevention in patients with recent ischemic stroke or transient ischemic attack
Common side effects
- Bleeding
- Gastrointestinal bleeding
- Dyspepsia
- Bruising
- Thrombotic thrombocytopenic purpura (TTP)
Key clinical trials
- The Effect and Safety of Combined Anti-platelet Treatment in Acute Ischemic Stroke Due to Large Artery Atherosclerosis (PHASE4)
- Randomized Clinical Trial of Endovascular Recanalization for Symptomatic Non-Acute Intracranial Artery Occlusion（REPAIR） (NA)
- Testing a New Treatment Strategy to Improve Secondary Stroke Prevention for Older Adults: The STROKE75+ Trial (PHASE3)
- Optimal Antiplatelet and Lipid Therapy in ACS With DES: OPACT Trial (NA)
- HR-MRI-Directed Tirofiban Therapy for Late-Window Acute Ischemic Stroke (TIAN) (PHASE3)
- Precision Antiplatelet Therapy Guided by Platelet Aggregation Function in Patients With Acute Ischemic STROKE (PHASE3)
- Appropriate Duration of Anti-Platelet straTegy in Patients With Advance Chronic Kidney Disease After New Generation Drug Eluting Stents (ADAPT-CKD) (NA)
- Colchicine Treatment for Non-Flow-Limiting Coronary Plaque by Coronary CTA: A Randomized Controlled Trial (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Aspirin combined with clopidogrel CI brief — competitive landscape report
- Aspirin combined with clopidogrel updates RSS · CI watch RSS
- The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School portfolio CI
Frequently asked questions about Aspirin combined with clopidogrel
What is Aspirin combined with clopidogrel?
How does Aspirin combined with clopidogrel work?
What is Aspirin combined with clopidogrel used for?
Who makes Aspirin combined with clopidogrel?
What drug class is Aspirin combined with clopidogrel in?
What development phase is Aspirin combined with clopidogrel in?
What are the side effects of Aspirin combined with clopidogrel?
What does Aspirin combined with clopidogrel target?
Related
- Drug class: All Dual antiplatelet agent drugs
- Target: All drugs targeting Cyclooxygenase (COX) and P2Y12 receptor
- Manufacturer: The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School — full pipeline
- Therapeutic area: All drugs in Cardiovascular
- Indication: Drugs for Acute coronary syndrome
- Indication: Drugs for Secondary prevention after myocardial infarction
- Indication: Drugs for Prevention of stent thrombosis after percutaneous coronary intervention
- Compare: Aspirin combined with clopidogrel vs similar drugs
- Pricing: Aspirin combined with clopidogrel cost, discount & access